A novel quantitative immunoassay system for p53 using antibodies selected for optimum designation of p53 status

Journal of Clinical Pathology

Volumn 50, Issue 2, 1997, Pages 143-147

  Thomas, M D ^a   McIntosh, G G ^a   Andersen, J J ^a   McKenna, D M ^a   Parr, A H ^a   Johnstone, R ^a   Lennard, T W J ^b   Horne, C H W ^a   Angus, B ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Department of Clinical Surgery ^*

Author keywords

Immunohitochemistry; p53; p53 antibodies; Quantitative ELISA; Western blot

Indexed keywords

PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; TECHNIQUE;

EID: 0031044713     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.50.2.143     Document Type: Article

References (14)

1. Lane DL. P53 guardian of the genome. Nature 1992;358:15-16.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science 1991;253:49-53.
3. Nigro JM, Baker SJ, Preisinger AC, Jessop JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
4. Bartek J, Bartkova J, Voijesek B, Staskova Z, Lukas J, Rejthar A, et al Aberrant expression of the p53 onco-protein is a common feature of a wide spectrum of human malignancies. Oncogene 1991;6:1699-703.
5. Horne GM, Anderson JJ, Tiniakos DG, McIntosh GG, Thomas MD, Angus B, et al P53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer 1986; 73:29-35.
6. Elledge RM, Fuqua SAW, Clark GM, Pujol P, Allred G, McGuire WL. Prognostic significance of p53 gene alterations in node negative breast cancer. Breast Cancer Res Treat 1993;26:225-35.
7. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Takamura S, Fukutomi T, et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. J Cancer Res 1991;82: 835-40.
8. Thomas MD, Parr AH, McIntosh GG, Anderson JJ, Ellis I, Nicholson R, et al. Measurement of p53 protein in human breast cancer: comparison between immunohistochemistry and semi-quantitative ELISA values. J Pathol 1995; 176(Suppl):172.
9. Vojtesek B, Fisher CJ, Barnes DM, Lane DP. Comparison between p53 staining in tissue sections and p53 protein levels measured by ELISA technique. Br J Cancer 1993;67: 1254-8.
10. Levesque MA, Diamandis EP, Yu H, Sutherland JA. Quantitative analysis of mutant p53 protein in breast tumour cytosols and study of its association with other biochemical prognostic indicators in breast cancer. Breast Cancer Res Treat 1994;30:179-95.
11. Hassapoglidou S, Diamandis EP, Sutherland DJA. Quantification of p53 protein in tumour cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. Oncogene 1992;8:1501-9.
12. Banks L, Matlashewski G, Crawford L. Isolation of human p53 specific monoclonal antibodies and their use in the study of human p53 expression. Eur J Biochem 1986;159: 529-34.
13. Stephen CW, Heiminen P, Lane DP. Characterisation of epitopes on human p53 using phage displayed peptide libraries: Insight into antibody peptide interactions. J Mol Biol 1995;248:58-78.
14. Stephen CW, Lane DP. Mutant conformation of p53. Precise epitope mapping using filamentous phage epitope library. J Mol Biol 1992;225:577-83.